Section Arrow
Quote
ZNTL.NASDAQ
- Zentalis Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/04 13:15 EST
Regular Hours
Last
 1.355
-0.085 (-5.90%)
Day High 
1.43 
Prev. Close
1.44 
1-M High
1.84 
Volume 
510.78K 
Bid
1.35
Ask
1.36
Day Low
1.35 
Open
1.4 
1-M Low
1.43 
Market Cap 
103.88M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.6 
20-SMA 1.6 
50-SMA 1.6 
52-W High 4.44 
52-W Low 1.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.28/-1.56
Enterprise Value
143.45M
Balance Sheet
Book Value Per Share
3.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.1581-0.2819-5.18%-- 
RANIRani Therapeutics Holdings2.275+0.125+5.81%-- 
SRPTSarepta Therapeutics16.8965-7.5535-30.89%15.76PE
NUVBNuvation Bio4.88-0.29-5.61%-- 
PRLDPrelude Therapeutics1.6701-2.3099-58.04%-- 
Quotes are at least 15-min delayed：2025/11/04 13:15 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.